13 USD
-0.47 (-3.49%)
13 USD
0 (0%)
Taking everything into account, IART scores 4 out of 10 in our fundamental rating. IART was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While IART is still in line with the averages on profitability rating, there are concerns on its financial health. IART has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
IART had positive earnings in the past year.
IART had a positive operating cash flow in the past year.
IART had positive earnings in 4 of the past 5 years.
In the past 5 years IART always reported a positive cash flow from operatings.
1.2 Ratios
IART has a Return On Assets (-13.58%) which is in line with its industry peers.
With a Return On Equity value of -47.74%, IART perfoms like the industry average, outperforming 52.94% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 4.27%, IART is in the better half of the industry, outperforming 74.87% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for IART is below the industry average of 8.82%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.58% | ||
| ROE | -47.74% | ||
| ROIC | 4.27% |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
1.3 Margins
IART has a Operating Margin of 10.22%. This is in the better half of the industry: IART outperforms 78.61% of its industry peers.
In the last couple of years the Operating Margin of IART has declined.
With a Gross Margin value of 57.21%, IART perfoms like the industry average, outperforming 56.68% of the companies in the same industry.
IART's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.22% | ||
| PM (TTM) | N/A | ||
| GM | 57.21% |
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
2. Health
2.1 Basic Checks
IART has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
IART has less shares outstanding than it did 1 year ago.
IART has less shares outstanding than it did 5 years ago.
IART has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.26, we must say that IART is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IART (1.26) is comparable to the rest of the industry.
IART has a Debt/Equity ratio of 1.73. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.73, IART is doing worse than 79.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.26 |
ROIC/WACC0.76
WACC5.64%
2.3 Liquidity
IART has a Current Ratio of 3.14. This indicates that IART is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.14, IART is in line with its industry, outperforming 58.29% of the companies in the same industry.
A Quick Ratio of 1.80 indicates that IART should not have too much problems paying its short term obligations.
IART has a Quick ratio (1.80) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.14 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
The earnings per share for IART have decreased by -4.44% in the last year.
Measured over the past years, IART shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.35% on average per year.
The Revenue has been growing slightly by 4.99% in the past year.
IART shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.20% yearly.
EPS 1Y (TTM)-4.44%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%31.71%
Revenue 1Y (TTM)4.99%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%5.57%
3.2 Future
IART is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.68% yearly.
Based on estimates for the next years, IART will show a small growth in Revenue. The Revenue will grow by 2.39% on average per year.
EPS Next Y-12.33%
EPS Next 2Y-3.14%
EPS Next 3Y1.48%
EPS Next 5Y2.68%
Revenue Next Year1.09%
Revenue Next 2Y1.9%
Revenue Next 3Y2.45%
Revenue Next 5Y2.39%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 5.49 indicates a rather cheap valuation of IART.
Compared to the rest of the industry, the Price/Earnings ratio of IART indicates a rather cheap valuation: IART is cheaper than 97.86% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of IART to the average of the S&P500 Index (26.43), we can say IART is valued rather cheaply.
With a Price/Forward Earnings ratio of 5.41, the valuation of IART can be described as very cheap.
99.47% of the companies in the same industry are more expensive than IART, based on the Price/Forward Earnings ratio.
IART is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.66, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.49 | ||
| Fwd PE | 5.41 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IART indicates a rather cheap valuation: IART is cheaper than 94.65% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 7.97 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.14%
EPS Next 3Y1.48%
5. Dividend
5.1 Amount
IART does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
13
-0.47 (-3.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners95.55%
Inst Owner Change0%
Ins Owners3.07%
Ins Owner Change0.07%
Market Cap1.01B
Revenue(TTM)1.64B
Net Income(TTM)-495.33M
Analysts54.12
Price Target15.81 (21.62%)
Short Float %9.95%
Short Ratio6.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.96%
Min EPS beat(2)2.22%
Max EPS beat(2)21.7%
EPS beat(4)3
Avg EPS beat(4)7.07%
Min EPS beat(4)-6.76%
Max EPS beat(4)21.7%
EPS beat(8)4
Avg EPS beat(8)3.13%
EPS beat(12)6
Avg EPS beat(12)3.64%
EPS beat(16)8
Avg EPS beat(16)4.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.86%
Min Revenue beat(2)-4.85%
Max Revenue beat(2)3.14%
Revenue beat(4)1
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-4.85%
Max Revenue beat(4)3.14%
Revenue beat(8)1
Avg Revenue beat(8)-1.23%
Revenue beat(12)2
Avg Revenue beat(12)-1.2%
Revenue beat(16)3
Avg Revenue beat(16)-0.96%
PT rev (1m)-8.82%
PT rev (3m)-5.65%
EPS NQ rev (1m)-1.23%
EPS NQ rev (3m)-12.58%
EPS NY rev (1m)0.04%
EPS NY rev (3m)-0.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.75%
Revenue NY rev (1m)-0.24%
Revenue NY rev (3m)-2.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.49 | ||
| Fwd PE | 5.41 | ||
| P/S | 0.62 | ||
| P/FCF | N/A | ||
| P/OCF | 11.34 | ||
| P/B | 0.98 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.97 |
EPS(TTM)2.37
EY18.23%
EPS(NY)2.4
Fwd EY18.48%
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)1.15
OCFY8.82%
SpS21.09
BVpS13.32
TBVpS-9.47
PEG (NY)N/A
PEG (5Y)N/A
Graham Number26.65
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.58% | ||
| ROE | -47.74% | ||
| ROCE | 5.11% | ||
| ROIC | 4.27% | ||
| ROICexc | 4.65% | ||
| ROICexgc | 11.32% | ||
| OM | 10.22% | ||
| PM (TTM) | N/A | ||
| GM | 57.21% | ||
| FCFM | N/A |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
ROICexc(3y)6.8%
ROICexc(5y)7%
ROICexgc(3y)25.35%
ROICexgc(5y)25.69%
ROCE(3y)7.3%
ROCE(5y)7.36%
ROICexgc growth 3Y-1.99%
ROICexgc growth 5Y0.59%
ROICexc growth 3Y-12.19%
ROICexc growth 5Y-7.26%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
F-Score5
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 5.62 | ||
| Cap/Depr | 68.73% | ||
| Cap/Sales | 6.32% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 28.01% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.14 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | 1.26 |
F-Score5
WACC5.64%
ROIC/WACC0.76
Cap/Depr(3y)58.38%
Cap/Depr(5y)54.07%
Cap/Sales(3y)4.82%
Cap/Sales(5y)4.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.44%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%31.71%
EPS Next Y-12.33%
EPS Next 2Y-3.14%
EPS Next 3Y1.48%
EPS Next 5Y2.68%
Revenue 1Y (TTM)4.99%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%5.57%
Revenue Next Year1.09%
Revenue Next 2Y1.9%
Revenue Next 3Y2.45%
Revenue Next 5Y2.39%
EBIT growth 1Y-9.4%
EBIT growth 3Y-13.07%
EBIT growth 5Y-6.81%
EBIT Next Year17.44%
EBIT Next 3Y9.51%
EBIT Next 5Y8.11%
FCF growth 1Y-113.18%
FCF growth 3Y-61.56%
FCF growth 5Y-31.13%
OCF growth 1Y-46.39%
OCF growth 3Y-25.46%
OCF growth 5Y-10.98%
INTEGRA LIFESCIENCES HOLDING / IART FAQ
Can you provide the ChartMill fundamental rating for INTEGRA LIFESCIENCES HOLDING?
ChartMill assigns a fundamental rating of 4 / 10 to IART.
Can you provide the valuation status for INTEGRA LIFESCIENCES HOLDING?
ChartMill assigns a valuation rating of 6 / 10 to INTEGRA LIFESCIENCES HOLDING (IART). This can be considered as Fairly Valued.
How profitable is INTEGRA LIFESCIENCES HOLDING (IART) stock?
INTEGRA LIFESCIENCES HOLDING (IART) has a profitability rating of 4 / 10.
What is the financial health of INTEGRA LIFESCIENCES HOLDING (IART) stock?
The financial health rating of INTEGRA LIFESCIENCES HOLDING (IART) is 3 / 10.